Dr. Chanock received his M.D. from Harvard Medical School in 1983 and completed clinical training in pediatrics, pediatric infectious diseases, and pediatric hematology/oncology and research training in molecular genetics at Boston Children's Hospital and the Dana-Farber Cancer Institute, Boston. Afterwards, he joined the National Cancer Institute, initially in the Pediatric Oncology Branch where he became a Senior Investigator. Several years ago he transitioned to the Division of Cancer Epidemiology and Genetics, where he has lead a highly productive program mapping cancer susceptibility genes. In 2001, he became director of the NCI Core Genotyping Facility and in 2005 he became co-leader of the Cancer Genetic Markers of Susceptibility (CGEMS) project. In 2007, he became the Chief of the newly formed Laboratory of Translational Genomics. Dr. Chanock has published nearly 600 peer review papers and recently received the prestigious Moyent and Rothschild Sabbatical Award at the Institute Curie in Paris, France.
If you are interested in learning more about TIGER 21, please complete the contact form and you will receive a copy of our most recent Asset Allocation Report.